Clinical Trials Logo

Clinical Trial Summary

Attention Deficit/Hyperactivity Disorder (ADHD) is one the most prevalent mental disorders among children and adolescents, with a prevalence of 5% in western culture. The basics of the disorder: inattentive and hyperactive/impulsive behaviors that manifest in a variety of settings causing a dysfunction in everyday life. ADHD can be subdivided into three sub-types: predominantly inattentive, predominantly hyperactive/impulsive or combined type. Common co-morbidities of ADHD are disruptive disorders; Oppositional defiant disorder (ODD) being the major one with about half of children with the combined sub-type ADHD and about a quarter of children with the predominantly inattentive also suffering from ODD. Conduct disorder is a co-morbidity for about a quarter of children with the combined sub-type ADHD. The co-occurrence of these disorders is thought to have a negative effect on the outcome of both of them.

Methylphenidate (MPH), short or long acting, is the mainstay of medical treatment for ADHD patients, it's efficacy proven in a variety of studies. It should be noted that MPH has also been proven to have a beneficial effect on children with disruptive behaviors. For children with disruptive disorders Risperidone is the mainstay of medical treatment, and has been proven in clinical trials.

To the best of their knowledge, a "head to head" study comparing these two drugs for the treatment of pediatric patients with ADHD and co-morbidity of disruptive disorders was never done before. The investigators aim is to examine the efficacy and tolerability of MPH vs. Risperidone in this population. In addition, the investigators will apply DSM5's cross cutting symptom measures scales is order to further define this unique subset of patients.

Disruptive mood dysregulation disorder (DMDD) is a new diagnosis in the latest version of the diagnostic and statistical manual (DSM5). It's main features: sever recurrent temper outbursts that are inconsistent with developmental level and occur on average three times a week, the outbursts occur in at least two settings and the mood between outbursts is irritable or angry. This diagnosis is in the differential diagnosis of ADHD with disruptive disorders.


Clinical Trial Description

Secondary study aims:

1. Comparing the efficacy and tolerability of MPH vs. Risperidone in the treatment of depressive symptoms in children and adolescents with ADHD and disruptive disorders.

2. Comparing the efficacy and tolerability of MPH vs. Risperidone in the treatment of manic symptoms in children and adolescents with ADHD and disruptive disorders.

3. Comparing the impact of MPH vs. Risperidone on overall every day functioning of children and adolescents with ADHD and disruptive disorder.

4. Comparing the impact of MPH vs. Risperidone on nighttime sleep of children and adolescents with ADHD and disruptive disorder.

5. Comparing the impact of MPH vs. Risperidone on weight and height of children and adolescents with ADHD and disruptive disorder.

6. Assessing the overlap between the diagnosis of ADHD and disruptive disorders and DMDD.

7. Assessing mood disorders and response to MPH vs. Risperidone treatment in children and adolescents with ADHD and disruptive disorder. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02063945
Study type Interventional
Source Sheba Medical Center
Contact
Status Terminated
Phase Phase 4
Start date February 1, 2017
Completion date February 1, 2018

See also
  Status Clinical Trial Phase
Completed NCT03535805 - Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances N/A
Recruiting NCT05449002 - Digital Single Session Intervention for Youth Mental Health N/A
Withdrawn NCT02247986 - Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder Phase 1/Phase 2
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02485587 - Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents N/A
Completed NCT00819429 - Supplements and Social Skills Intervention Study N/A
Completed NCT00626236 - Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems Phase 2
Completed NCT01085305 - The Effectiveness of Parent-Child Interaction Therapy (PCIT) N/A
Completed NCT00250354 - A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Phase 3
Completed NCT00000385 - Long-Term Lithium Treatment for Aggressive Conduct Disorder Phase 3
Withdrawn NCT01443949 - Teenagers, Drug Addiction, and Reward and Impulse Control
Completed NCT04091633 - School Health Implementation Network: Eastern Mediterranean N/A
Completed NCT02563145 - Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents N/A
Completed NCT02766101 - Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges N/A
Completed NCT00404911 - Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth N/A
Completed NCT00051727 - Prevention of School Dropout for Mexican American Adolescents Phase 2
Completed NCT02998073 - Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder N/A
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Recruiting NCT06373484 - Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents N/A
Recruiting NCT05637320 - Big Feelings: A Study on Children's Emotions in Therapy N/A